Cadila Pharmaceuticals on Monday announced the launch of an aqueous formulation of cholecalciferol to treat Vitamin D deficiency. According to the company’s statement, it is the world’s first aqueous formulation innovation that demonstrates superior pharmacokinetics (PK) and pharmacodynamics (PD) compared to traditional oil-based
cholecalciferol preparations available in the market.
Vitamin D deficiency is a major health concern globally, contributing significantly to the outcomes of various diseases. Cadila Pharmaceuticals’ innovative aqueous cholecalciferol injection offers a unique solution with rapid correction of Vitamin D deficiency in short period. This breakthrough not only enhances the efficacy of treatment but also ensures a painless and easy administration process, marking a significant advancement in patient care.
Key Features of Cadila Pharmaceuticals’ Aqueous Cholecalciferol Injection:
- Superior Pharmacokinetics and Pharmacodynamics: The novel aqueous formulation demonstrates significant improvements in both pharmacokinetic and pharmacodynamics properties of the drug , outperforming conventional oil-based cholecalciferol preparations.
- Rapid Correction of Vitamin D Deficiency: Patients can benefit from a swift correction of Vitamin D deficiency in short span of time, addressing a critical need for expedited treatment outcomes in many major illnesses.
- Painless Administration: The injection is designed for ease of use, providing a painless experience for patients, promoting better compliance with treatment regimens.
Addressing Multifactorial Health Conditions:
The significance of Vitamin D extends well beyond bone health, influencing outcomes in various conditions such as Cardiovascular Disease, Diabetes Mellitus, and weakened immune systems. Vitamin D acts as an anti-hypertrophic agent, a stimulator of vascular smooth muscle cell proliferation, anti-fibrotic, antioxidant, anti-inflammatory, and an inhibitor of the Renin-Angiotensin-Aldosterone System (RAAS).
Cadila Pharmaceuticals recognizes the pivotal role Vitamin D plays in overall health and aims to revolutionize its treatment for better outcomes in multitude of major medical illnesses.
By introducing the world’s first aqueous cholecalciferol injection, through totally indigenous research, the company envisions a paradigm shift in addressing Vitamin D deficiency globally.
“Our commitment to innovation and patient centric research to bridge the gap in areas of unmet medical need has driven the development of this ground-breaking aqueous cholecalciferol injection. We believe this advancement will redefine the landscape of Vitamin D deficiency treatment and ensure better treatment outcomes,” Dr. Rajiv I. Modi, Chairman and Managing Director, Cadila Pharmaceuticals said.